This grant funds research to develop and advance monoclonal antibody therapies for prevention and treatment of emerging or re-emerging viral infections caused by viruses such as Ebola, Marburg, Crimean-Congo Hemorrhagic Fever, Rift Valley Fever, Enterovirus D68, and Chikungunya. Proposals should focus on in-vitro and in-vivo characterization of antibody candidates derived from single cell clones, aiming to enable clinical trials and strengthen global preparedness against viral epidemics and pandemics.
Eligible applicants include legal entities established in EU member states, associated countries, and the United States. Applicants must comply with admissibility conditions, proposal page limits, and layout requirements as described in the Horizon Europe Work Programme General Annexes. Specific eli
